DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Effect of Tiotropium on Inflammation and Exacerbations in COPD

Information source: Royal Free and University College Medical School
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Chronic Obstructive Pulmonary Disease

Intervention: tiotropium (Drug)

Phase: Phase 4

Status: Completed

Sponsored by: Royal Free and University College Medical School

Official(s) and/or principal investigator(s):
Jadwiga A Wedzicha, MD, Principal Investigator, Affiliation: Academic Unit of Respiratory Medicine, Royal Free and University College Medical School

Summary

Patients with COPD experience exacerbations that are a major cause of morbidity. Exacerbations are associated with increased airway and systemic inflammation and those experiencing frequent exacerbations demonstrate increased inflammation in the stable state. Tiotropium has been shown to reduce exacerbation frequency and it might be postulated that this is due to a reduction in inflammation. The study will compare airway inflammation and exacerbation frequency in patients with COPD on tiotropium or placebo.

Clinical Details

Official title: A Randomised, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Changes in Inflammatory Markers in Induced Sputum Following Treatment With Tiotropium Inhalation Capsules 18mcg Once Daily in Patients With Chronic Obstructive Pulmonary Disease

Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment

Primary outcome: sputum IL-6

Secondary outcome:

sputum IL-8

sputum MPO

serum IL-6

serum CRP

exacerbation frequency

FEV1

FVC

Detailed description: Patients with COPD will be randomised to tiotropium or placebo in addition to their usual medication. They will be followed prospectively over 1 year and provide sputum for quantification of IL-6 and IL-8 at baseline and at 3 monthly intervals. Serum IL-6 will also be quantified at baseline and over the year. Changes in inflammatory markers will be assessed by analysis of area under the curve of log transformed data. Exacerbation frequency will be calculated from patient diary cards using a previously validated symptom-based exacerbation definition.

Eligibility

Minimum age: N/A. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- diagnosis of COPD,

- FEV1 < 80% predicted,

- minimum 10 pack year smoking history

Exclusion Criteria:

- asthma,

- atopic disease,

- eosinophilia,

- history of malignancy,

- history of clinically significant pulmonary disease

Locations and Contacts

London Chest Hospital, London, United Kingdom
Additional Information

Starting date: October 2002
Last updated: November 27, 2006

Page last updated: August 20, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017